GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » Shiller PE Ratio

Sequenom (Sequenom) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sequenom Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sequenom Shiller PE Ratio Historical Data

The historical data trend for Sequenom's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom Shiller PE Ratio Chart

Sequenom Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sequenom Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sequenom's Shiller PE Ratio

For the Biotechnology subindustry, Sequenom's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequenom's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sequenom's Shiller PE Ratio falls into.



Sequenom Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sequenom's E10 for the quarter that ended in Jun. 2016 is calculated as:

For example, Sequenom's adjusted earnings per share data for the three months ended in Jun. 2016 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2016 (Change)*Current CPI (Jun. 2016)
=-0.05/101.6881*101.6881
=-0.050

Current CPI (Jun. 2016) = 101.6881.

Sequenom Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200609 -0.139 85.606 -0.165
200612 -0.150 85.142 -0.179
200703 -0.113 86.640 -0.133
200706 -0.126 87.906 -0.146
200709 -0.140 87.964 -0.162
200712 -0.190 88.616 -0.218
200803 -0.190 90.090 -0.214
200806 -0.210 92.320 -0.231
200809 -0.180 92.307 -0.198
200812 -0.260 88.697 -0.298
200903 -0.290 89.744 -0.329
200906 -0.330 91.003 -0.369
200909 -0.240 91.120 -0.268
200912 -0.300 91.111 -0.335
201003 -0.270 91.821 -0.299
201006 -0.860 91.962 -0.951
201009 -0.300 92.162 -0.331
201012 -0.250 92.474 -0.275
201103 -0.130 94.283 -0.140
201106 -0.210 95.235 -0.224
201109 -0.190 95.727 -0.202
201112 -0.230 95.213 -0.246
201203 -0.220 96.783 -0.231
201206 -0.260 96.819 -0.273
201209 -0.260 97.633 -0.271
201212 -0.290 96.871 -0.304
201303 -0.260 98.209 -0.269
201306 -0.270 98.518 -0.279
201309 -0.240 98.790 -0.247
201312 -0.160 98.326 -0.165
201403 -0.130 99.695 -0.133
201406 0.040 100.560 0.040
201409 -0.050 100.428 -0.051
201412 0.160 99.070 0.164
201503 0.110 99.621 0.112
201506 -0.080 100.684 -0.081
201509 -0.080 100.392 -0.081
201512 -0.100 99.792 -0.102
201603 -0.110 100.470 -0.111
201606 -0.050 101.688 -0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sequenom  (NAS:SQNM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sequenom Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sequenom's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequenom (Sequenom) Business Description

Traded in Other Exchanges
N/A
Address
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
Executives
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler director
Charles P Slacik director 250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton officer: Sr VP, GC & Secretary 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver officer: SVP & CFO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas director
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii director, officer: Chairman, President & Sec 22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg director, officer: EVP and Treasurer P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis director REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch officer: President & CEO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Sequenom (Sequenom) Headlines

From GuruFocus

Sequenom Officer Acquires 30,000 Shares

By Jennifer Chiou Jennifer Chiou 05-10-2016

Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares

By GuruFocus GuruFocus 08-03-2012

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010

Context Capital Management's Top Buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-15-2015